ArticleJournal of experimental & clinical cancer research : CR2022

High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma.

Yuanyan Tang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.